La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Argent BioPharma Croissance future

Future contrôle des critères 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Argent BioPharma.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	28.4%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

Feb 21

What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

Dec 30

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Argent BioPharma n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

ASX:RGT - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2023	1	-17	-13	-13	N/A
9/30/2023	2	-19	-13	-13	N/A
6/30/2023	3	-21	-12	-12	N/A
3/31/2023	4	-22	-13	-13	N/A
12/31/2022	5	-23	-14	-14	N/A
9/30/2022	5	-22	-14	-13	N/A
6/30/2022	5	-20	-15	-12	N/A
3/31/2022	5	-19	-15	-12	N/A
12/31/2021	5	-18	-16	-12	N/A
9/30/2021	4	-17	-15	-12	N/A
6/30/2021	3	-16	-15	-12	N/A
12/31/2020	1	-13	-12	-10	N/A
9/30/2020	2	-16	-12	-10	N/A
6/30/2020	2	-19	-11	-10	N/A
12/31/2019	2	-18	-10	-10	N/A
9/30/2019	1	-14	-8	-8	N/A
6/30/2019	1	-11	-7	-6	N/A
12/31/2018	1	-7	-6	-6	N/A
9/30/2018	0	-7	-6	-6	N/A
6/30/2018	0	-8	-6	-6	N/A
3/31/2018	0	-10	-6	-6	N/A
12/31/2017	0	-12	-6	-5	N/A
9/30/2017	0	-10	N/A	-5	N/A
6/30/2017	0	-8	N/A	-5	N/A
3/31/2017	0	-7	N/A	-5	N/A
12/31/2016	0	-6	N/A	-4	N/A
9/30/2016	0	-6	N/A	-4	N/A
6/30/2016	0	-6	N/A	-3	N/A
3/31/2016	0	-6	N/A	-2	N/A
12/31/2015	0	-6	N/A	-2	N/A
9/30/2015	0	-5	N/A	-1	N/A
6/30/2015	N/A	-4	N/A	-1	N/A
3/31/2015	0	-5	N/A	-1	N/A
12/31/2014	0	-6	N/A	0	N/A
9/30/2014	0	-6	N/A	0	N/A
6/30/2014	0	-5	N/A	0	N/A
3/31/2014	0	-3	N/A	-1	N/A
12/31/2013	0	0	N/A	-1	N/A
9/30/2013	0	-1	N/A	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if RGT's forecast earnings growth is above the savings rate (2.4%).

Bénéfices vs marché: Insufficient data to determine if RGT's earnings are forecast to grow faster than the Australian market

Croissance élevée des bénéfices: Insufficient data to determine if RGT's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: Insufficient data to determine if RGT's revenue is forecast to grow faster than the Australian market.

Croissance élevée des revenus: Insufficient data to determine if RGT's revenue is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if RGT's Return on Equity is forecast to be high in 3 years time

Argent BioPharma Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased to AU$0.04

Price target decreased to AU$0.07

Recent updates

New minor risk - Share price stability

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New major risk - Market cap size

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Price target decreased to AU$0.04

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

Price target decreased to AU$0.07

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding

Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

Full year 2021 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil

Full year 2021 earnings released: AU$0.007 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System

Mgc Pharmaceuticals Limited Announces Phase Iii Cimetra Clinical Trial Commences

MGC Pharmaceuticals Limited Announces Cannabis Derived Epilepsy Investigational Medicinal Product

Mgc Pharmaceuticals Ltd Provides Progress Report on Major Clinical Trial Programs Planned for 2021

MGC Pharmaceuticals Ltd Announces Further Results from the Phase II Clinical and Preclinical Studies on ArtemiC(TM)

Joint Company Secretary has left the company

MGC Pharmaceuticals Limited Revives Increased Initial Supply Agreement for ArtemiC

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns